Obstructive Hypertrophic Cardiomyopathy (oHCM) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030
Hypertrophic cardiomyopathy is a genetic disorder characterized by marked hypertrophy of the myocardium. It is frequently accompanied by dynamic left ventricular outflow tract obstruction and dyspnea, angina, and syncope symptoms. Obstructive Hypertrophic Cardiomyopathy (oHCM) is defined as HCM with left ventricular outflow tract obstruction causing a peak left ventricular outflow gradient of at least 30 mm Hg is observed in approximately 70% of patients with HCM frequently leads to symptoms including dyspnea, fatigue, chest pain, or syncope. The unique pathophysiology underlying the obstruction is its functional dynamic nature, greatly influenced by alterations in the load imposed on the left ventricle and its contractility. The block's initial therapy for symptomatic patients is medical therapy with β-blockers and calcium antagonists. However, a subset of patients have continued severe symptoms, which are unresponsive to medical treatment.
Hypertrophic
cardiomyopathy (HCM) is a cardiac disorder affecting approximately 0.2–0.5% of
the adult population, amongst which 50% to 70% of patients represent
Obstructive Hypertrophic Cardiomyopathy (oHCM).
The competitive
landscape of Obstructive Hypertrophic Cardiomyopathy (oHCM) includes country-specific
approved and pipeline therapies. Any asset/product-specific designation or
review and Accelerated Approval are tracked and supplemented with analyst
commentary.
KOLs insights of Obstructive
Hypertrophic Cardiomyopathy (oHCM) across 8 MM market from the center of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Obstructive
Hypertrophic Cardiomyopathy (oHCM) Market Forecast:
Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data
Inputs with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
S. No Asset Company Stage
1 mavacamten MyoKardia,
Inc. Phase 3
2 CK-3773274 Cytokinetics Phase 2
3 Aficamten Cytokinetics,
Incorporated Phase 2
Comments
Post a Comment